The FRRS1 gene exhibits NMD insensitivity in one experiment (GSE16170) using two treatments (Ago2 siRNA - targets CBP80/20-bound mRNAs and thus considered a regulator of NMD and UPF1 and Ago2 siRNA), and NMD sensitivity in another experiment, in mononuclear leukocytes of prostate cancer patients but not of healthy patients (GSE24204). The gene discussed is FRRS1; the disease is prostate carcinoma.